Last updated: February 13, 2026
What is NDC 14539-0700?
NDC 14539-0700 refers to a specific drug product registered under the National Drug Code (NDC) system. Based on current available data, this NDC corresponds to Bupivacaine Hydrochloride Injection, USP. It is used as a local anesthetic and for analgesia during surgical procedures. The drug is marketed primarily for hospital and outpatient use.
Market Context and Demand Drivers
-
Medical Use and Indications: Bupivacaine injection remains a standard local anesthetic, especially suited for epidural, nerve block, and infiltration anesthesia. It has a well-established profile with predictable demand for surgical, obstetric, and pain management settings.
-
Market Size: The global local anesthetics market was valued at approximately USD 1.65 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.8% from 2023 to 2030 (source: Market Research Future). The U.S. accounts for a significant segment, driven by the high volume of surgeries and pain management procedures, with an estimated market share of around 40%.
-
Competition: The market features several competitors including local anesthetics like lidocaine, ropivacaine, and tetracaine. Bupivacaine's longer duration of action and potency give it a niche, but generic formulations have pressure on pricing.
-
Regulatory Environment: The FDA approved Bupivacaine for parenteral use in 1982. Post-approval, market entry is influenced by patent status; currently, the original patents have expired, enabling generics.
Market Share and Product Positioning
- Original branded formulations, such as Marcaine (by Hospira), once held a dominant market share.
- Generics have gained significant traction, reducing prices and market premiums.
- The availability of various formulations (e.g., 0.25%, 0.5%) tailored for specific uses influences sales volumes.
Pricing Landscape
Current Pricing Benchmarks
| Product Type |
Typical Price Range (per vial) |
Notes |
| Brand-name (e.g., Marcaine) |
USD 25 - 50 |
Higher margin, less price competition |
| Generic formulations |
USD 10 - 20 |
Market-dominant, increased competition |
Note: Prices vary by package size, region, and purchasing agreements.
Pricing Trends
- Post-patent expiry, generic prices typically fall 30-50% within 2-3 years.
- Hospital procurement prices tend to be lower than outpatient retail prices, with negotiated discounts often 10-20%.
- Supply chain disruptions (e.g., raw material shortages) during the COVID-19 pandemic pushed prices upward temporarily, but the trend has stabilized.
Price Projection (Next 5 Years)
-
Baseline Scenario: Continued generic erosion results in gradual price decline, with an average annual decrease of approximately 3-5%.
-
Optimistic Scenario: Introduction of biosimilar or alternative formulations could exert additional downward pressure, causing prices to decline by up to 10% annually in some segments.
-
Pessimistic Scenario: Supply chain constraints or regulatory changes affecting manufacturing license could temporarily inflate prices by 5-8%, but long-term trends remain downward due to market saturation.
| Year |
Price Range (per vial USD) (Generic) |
Notes |
| 2023 |
USD 10 - 20 |
Stable with minor fluctuations |
| 2025 |
USD 9 - 19 |
Slight decline driven by increased competition |
| 2030 |
USD 8 - 18 |
Assuming standard market erosion, no major disruptions |
Regulatory and Policy Impacts
- CMS (Centers for Medicare & Medicaid Services) updates on drug pricing and coverage could influence hospital procurement.
- Proposed Medicare reforms aiming at reducing drug costs may lead to further price compression.
- Any new safety or efficacy alerts could impact demand and pricing.
Key Factors Affecting Future Prices
- Patent status and expiration timelines.
- Emergence of new anesthetic agents.
- Manufacturing costs driven by raw material prices.
- Market entry of biosimilars or cheaper generics.
- Regulatory and reimbursement policies.
Conclusion
The market for NDC 14539-0700 (Bupivacaine Hydrochloride Injection) demonstrates ongoing stabilization with declining prices, driven primarily by generic competition. Prices are expected to decline by approximately 3-5% annually through 2030, assuming no significant regulatory or supply chain disruptions.
Key Takeaways
- The product faces intense generic competition, pressuring prices downward.
- The pricing trend aligns with global local anesthetic markets, which have seen consistent declines since patent expirations.
- Demand remains stable due to widespread use in surgical analgesia.
- Price sensitivity among hospitals and outpatient clinics influences procurement costs significantly.
- Future pricing will depend heavily on market entry of biosimilars and policy changes.
FAQs
Q1: How do patent expirations impact the pricing of NDC 14539-0700?
A1: Patent expirations enable generic manufacturers to produce lower-cost alternatives, leading to a significant decline in prices, often by 30-50% within a few years.
Q2: What factors could cause prices to increase in the near term?
A2: Supply chain disruptions, regulatory restrictions, or safety concerns could temporarily elevate prices.
Q3: How do hospital procurement practices influence the drug's market price?
A3: Hospitals often negotiate volume discounts, which lower acquisition costs, but prices paid can vary based on hospital size and negotiation power.
Q4: Are biosimilars expected to enter the market for this drug?
A4: Biosimilars are less relevant for small-molecule drugs like bupivacaine but similar oral or injectable versions could influence pricing.
Q5: What other competitive products influence NDC 14539-0700's market?
A5: Alternatives such as lidocaine, ropivacaine, and patent-expired formulations of other local anesthetics provide competitive pressure.
References
- Market Research Future, "Global Local Anesthetics Market," 2023.
- FDA database, "Approved Drug Products with Therapeutic Equivalence Evaluations," 2023.
- IQVIA, "Hospital and Retail Pharmaceutical Pricing Data," 2023.
[1] Market Research Future reports (2023).
